Monte Rosa reports Q4 2023 net loss $33.3M; cash into H1 2026; key pipeline milestones on track

Monte Rosa Therapeutics, Inc.

Net loss Q4 2023 $33.3M ($30.8M prior year); FY net loss $135.4M; cash $237M, runway into H1 2026.
MRT-2359 MYC-driven solid tumors Phase 1/2; recommended Phase 2 dose expected Q2 2024; Fast Track for SCLC and NSCLC.
MRT-6160 VAV1 MGD IND filing planned Q2 2024; Phase 1 SAD/MAD study start mid-2024.
MRT-8102 NEK7 program first development candidate nominated; IND submission targeted Q1 2025.
Entered Roche collaboration; $50M upfront, potential >$2B milestones plus royalties.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Monte Rosa Therapeutics, Inc. reported financial results for full year and fourth quarter ended December 31, 2023.

Period: full year and fourth quarter ended December 31, 2023
Result: reported results

Exact text from the filing

Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-031138

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.